Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle About Us menu options
Our Team
For Patients
Toggle For Patients menu options
About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
Multiple Myeloma
Amyloidosis
Other Plasma Cell Disorders
Toggle Other Plasma Cell Disorders menu options
Precursor Conditions to Multiple Myeloma
Myeloma Signs and Symptoms
Amyloidosis Signs and Symptoms
Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
Multiple Myeloma and Plasma Cell Disorder Treatment
Understanding and Managing Side Effects
Your First Visit
Toggle Your First Visit menu options
Self-Referral
Support Groups and Helpful Links
Frequently Asked Questions
Referring Physicians
Toggle Referring Physicians menu options
Refer a Patient
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 56 results
[
Author
]
Title
Type
Year
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
V
van Besien K
,
Koshy N
,
Gergis U
,
Mayer S
,
Cushing M
,
Rennert H
,
Reich-Slotky R
,
Mark T
,
Pearse R
,
Rossi A
et al.
. 2017.
Cord blood chimerism and relapse after haplo-cord transplantation.
.
Leuk Lymphoma. 58(2):288-297.
van Besien K
,
Koshy N
,
Gergis U
,
Mayer S
,
Cushing M
,
Rennert H
,
Reich-Slotky R
,
Mark T
,
Pearse R
,
Rossi A
et al.
. 2017.
Haplo-cord transplant: HLA-matching determines graft dominance.
.
Leuk Lymphoma. 58(6):1512-1514.
Vij R
,
Wang M
,
Jagannath S
,
Niesvizky R
,
Jakubowiak AJ
,
Kavalerchik E
,
Huang M
,
Siegel DS
. 2015.
Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
.
Leuk Lymphoma. 56(10):2959-61.
W
Wang M
,
Martin T
,
Bensinger W
,
Alsina M
,
Siegel DS
,
Kavalerchik E
,
Huang M
,
Orlowski RZ
,
Niesvizky R
. 2013.
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
.
Blood. 122(18):3122-8.
Wei X
,
M Calvo-Vidal N
,
Chen S
,
Wu G
,
Revuelta MV
,
Sun J
,
Zhang J
,
Walsh MF
,
Nichols KE
,
Joseph V
et al.
. 2018.
Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.
.
Cancer Res. 78(10):2747-2759.
A Wernicke G
,
Sabbas A
,
Kulidzhanov F
,
Shamis M
,
Golster Y
,
Niesvizky R
,
Lane J
. 2012.
A single-dose conformal delivery of radiotherapy following osteoplasty : a novel approach to treatment of osteolytic metastasis in the setting of multiple myeloma.
.
HSS J. 8(2):169-74.
« first
‹ previous
1
2
3
(current)